IPM Take
The argument over early high-efficacy treatment in multiple sclerosis is becoming less theoretical.
Ten-year follow-up from OPERA I and II found durable relapse suppression and disability control among patients continuously treated with ocrelizumab. More importantly, patients initially assigned to interferon and switched later still carried worse cumulative disability outcomes years after receiving the same high-efficacy therapy.
That is the politically difficult finding. A health system can delay an expensive treatment for two years and call it sequencing. The nervous system may call it lost time.
Executive Summary
The long-term analysis followed the original 1,656 participants from OPERA I and II, with 1,325 entering the open-label extension. Among continuously treated patients, more than 70% remained relapse-free over 10 years, while more than 80% remained free of 48-week confirmed disability progression and nearly 90% remained free of progression independent of relapse activity.
Nearly 95% of patients without walking impairment at baseline remained unrestricted in ambulation. Annual disease control remained high, with more than 84% achieving NEDA-3 in a given year.
No new or unexpected safety findings emerged over the 10-year period after excluding COVID-related events. Importantly, patients who began ocrelizumab approximately two years later after initial interferon treatment continued to show worse cumulative disability outcomes despite years of subsequent ocrelizumab exposure.
Why it matters
- This is no longer only a question of whether high-efficacy therapy controls relapses. It is a question of whether treatment timing changes what cannot later be recovered.
- For payers and public systems, the evidence makes restrictive escalation policies harder to defend when those policies force patients to accumulate disease activity before becoming eligible for more effective therapy.
MS treatment used to be organised around caution. Start with a lower-efficacy medicine, wait, and escalate if the disease proves aggressive enough.
That approach made intuitive sense when long-term safety evidence for stronger therapies was limited. It becomes harder to justify as the evidence matures.
The OPERA decade-long follow-up shows durable inflammatory control, preserved ambulation and relatively low disability accumulation with continuous ocrelizumab. More politically important is what happened to the patients who waited. Those initially assigned to interferon eventually received ocrelizumab too, but the disability gap did not disappear.
That is what neurologists mean when they say time is brain, spinal cord and function in MS. Delayed high-efficacy treatment is not always reversible by later giving the same drug.
The safety picture also matters. Ten-year exposure did not reveal a new time-dependent safety signal, although infection surveillance, immunoglobulin monitoring and long-term pharmacovigilance remain essential.
This does not mean every newly diagnosed patient must receive ocrelizumab. It means systems should stop pretending that forced therapeutic delay is neutral.
If two years of lower-efficacy treatment leave a measurable disability legacy eight years later, reimbursement sequencing becomes a clinical decision whether payers call it one or not.
